Ken Livak, PhD, Technology Group Lead for the newly formed Translational Immunogenomics Lab (TIGL) at Dana-Farber Cancer Institute. TIGL will use the latest genomic technologies to assess the response of the immune system to cancer and therapy. Ken did his PhD in Biochemistry and Molecular Biology at Harvard University.